Athenex announces exclusive license agreement with national cancer institute to utilize t cell receptors targeting mutated p53, kras, and egfr for the development of autologous and allogeneic cell therapies

Athenex plans to expand the allogeneic nkt cell r&d pipeline with these new licensed tcrs to target solid tumors athenex plans to expand the allogeneic nkt cell r&d pipeline with these new licensed tcrs to target solid tumors
ATNX Ratings Summary
ATNX Quant Ranking